Table 2.
Evaluation of the Infusion Sets During the Trial.
| Type of change | Faster aspart | Insulin aspart | Total | Evaluation |
|---|---|---|---|---|
| Routine at home | 210 | 98 | 308 | Macroscopic by subject |
| Routine at site visit | 147 | 72 | 219 | Macroscopic and microscopic by laboratory |
| Premature | 21 | 4 | 25 | Macroscopic by subject; plus macroscopic and microscopic by laboratory if shippeda |
| Unclassified | 1 | 0 | 1 | Macroscopic by subject |
| Total | 379 | 174 | 553 |
a
Three of the seven infusion sets that were changed prematurely because of a possible occlusion were shipped to the laboratory for macroscopic and microscopic evaluation (all in the faster aspart group).